TCGA-CV-6938-01A-11R-1915-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.032876712
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.770
- INTERFERON_GAMMA_RESPONSE+0.700
- ALLOGRAFT_REJECTION+0.580
- MYC_TARGETS_V1+0.480
- MYC_TARGETS_V2+0.470
- INFLAMMATORY_RESPONSE+0.440
- COMPLEMENT+0.410
- OXIDATIVE_PHOSPHORYLATION+0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.380
- P53_PATHWAY+0.360
Top 10 suppressed
- MYOGENESIS-0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
- HEDGEHOG_SIGNALING-0.290
- HYPOXIA-0.260
- KRAS_SIGNALING_DN-0.220
- SPERMATOGENESIS-0.180
- WNT_BETA_CATENIN_SIGNALING-0.160
- UV_RESPONSE_DN-0.140
- ESTROGEN_RESPONSE_EARLY-0.070
- ESTROGEN_RESPONSE_LATE+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_GJNCYABP | ATRT | — | 0.876 |
| 2 | SJEPD030292_D1.RNA-Seq | EPN | Supratentorial EPN | 0.871 |
| 3 | SRR6013516 | — | cohortA1 | 0.866 |
| 4 | 8f1213be-da41-4cd6-97b2-f9fce1ea00ff | — | — | 0.859 |
| 5 | SRR12696807 | — | — | 0.858 |
| 6 | 896B5096-D888-4DC3-9C70-152BDE083E26 | — | — | 0.856 |
| 7 | BS_8GW1TMV2 | Med | Medulloblastoma | 0.855 |
| 8 | TCGA-BA-5152-01A-02R-1873-07 | — | — | 0.848 |
| 9 | TCGA-39-5011-01A-01R-1443-07 | — | cohortA1 | 0.846 |
| 10 | 6D1D9992-DA2B-419A-A80A-9EBCDA831754 | — | — | 0.845 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.770 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.700 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.480 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.360 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| PEROXISOME | 0.320 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |